SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — John Henry Holliday

PatientJohn Henry Holliday
Date of birth2004-08-14
IdentifiersMRN HR-NI007-SYN; SSN (made up) 000-07-8153
Document date2026-04-14
AuthorMartin Beaumont, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

End of the intensive phase: two-month sputum and the start of the continuation phase. [S]

History of Present Illness

Mr. Holliday returns after nine weeks of treatment. He completed the 56 doses of the intensive phase six days ago, and pyrazinamide was stopped; he now takes isoniazid, rifampin, and pyridoxine daily by video. The cultures from the third week show no growth so far, with the final reading due next week. His cough has gone, and he has gained weight. He has had no nausea, yellowing, dark urine, or numbness. He has had no alcohol for seven weeks and sees his counselor every two weeks. He is working full days. [S]

ElementDetail
TreatmentIntensive phase complete; continuation phase started six days ago
SymptomsNo cough, fever, or night sweats
Weight62.5 kg, up 4.5 kg since diagnosis
AlcoholNone for seven weeks; AUDIT-C 1

Review of Systems

SystemResultFinding
RespiratoryNegativeNo cough, sputum, or blood
ConstitutionalNegativeNo fever or night sweats; appetite good
GastrointestinalNegativeNo nausea or abdominal pain
PsychiatricNegativeMood good; no thoughts of suicide or self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Isoniazid 300 mg tablet, one tablet daily300 mg once daily by video-observed therapy with the health department, seven days a week, for six monthsOral route2026-02-12 to 2026-08-13completedS
Rifampin 300 mg capsules, two capsules (600 mg) daily600 mg once daily on an empty stomach by video-observed therapy with the health department, seven days a week, for six monthsOral route2026-02-12 to 2026-08-13completedS
Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily1500 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phaseOral route2026-02-12 to 2026-04-08completedS
Ethambutol 400 mg tablets, three tablets (1200 mg) daily1200 mg once daily by video-observed therapy with the health department, seven days a week, until susceptibility results returnOral route2026-02-12 to 2026-03-10stoppedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route2026-02-12 to 2026-08-13completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-14Body height178cmS
2026-04-14Body weight62.5kgS
2026-04-14Body mass index (BMI) [Ratio]19.7kg/m2S
2026-04-14Systolic blood pressure116mm[Hg]S
2026-04-14Diastolic blood pressure74mm[Hg]S
2026-04-14Heart rate78/minS
2026-04-14Respiratory rate16/minS
2026-04-14Body temperature36.7CelS
2026-04-14Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma38U/L7-56 U/LNormalS
2026-04-14Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma35U/L10-40 U/LNormalS
2026-04-14Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.1-1.2 mg/dLNormalS
2026-04-14Total score [AUDIT-C]1{score}S

Physical Exam

Vital signs recorded on 2026-04-14; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 62.5 kg
EyesNo icterus
RespiratoryClear apart from a few fine crackles at the right apex
AbdomenLiver not enlarged or tender

Problems

ProblemClinical statusVerificationCodeProvenance
Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistanceactiveconfirmed A15.0S — Synthetic modern coding of his documented pulmonary tuberculosis at the time of diagnosis; the bacteriology is synthetic.
Alcohol use disorder, mild, with binge drinkingactiveconfirmed F10.10S — Synthetic modern coding anchored to the documented heavy drinking; the severity and the criteria met are synthetic.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationSymptom review: cough, sputum, hemoptysis, fever, night sweatsAt least monthly during treatmentCompleted todayNo symptoms
ExaminationWeightAt least monthly during treatmentCompleted today62.5 kg
Medication safetyHepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine)Every visit and every observed doseCompleted todayNone
LaboratoryLiver tests (ALT, AST, bilirubin)Baseline, at two weeks, then monthly because of alcohol useCompleted todayALT 38, AST 35 U/L, bilirubin 0.7 mg/dL, all normal
LaboratoryTwo-month sputum cultureAt the end of the intensive phase; decides the continuation length in cavitary diseaseCompleted todayInduced sputum smear negative today; culture sent, final reading in six weeks
LaboratorySputum AFB smear and cultureMonthly until two consecutive cultures are negativeCompleted todayThird-week cultures show no growth so far; final next week
ImagingChest X-rayAt diagnosis; at two months only if the first cultures were negative; at the end of treatment as a new baselineNot indicatedNot needed at two months, because the first cultures were positive
Medication safetyDoses observed and missed (video-observed therapy)Every visitCompleted todayAll 56 intensive-phase doses observed
Medication safetyPeripheral neuropathy check, with pyridoxineEvery visitCompleted todayNo neuropathy
ReferralContact investigation (household, coworkers, patients)Led by the health department, from diagnosisReferredHealth department continuing; no results are part of his record
SurveyAlcohol use (AUDIT-C for the past month)Every visitCompleted todayAUDIT-C 1 for the past month
Self-managementBrief counseling about alcohol and liver riskEvery visitCompleted todaySocial events planned for
ReferralCounseling with a substance-use counselorEvery one to two weeks during treatmentCompleted todayEvery two weeks
SurveySuicide-risk review and safety plan, with the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide
ReferralInfectious diseases reviewAt two months and at the end of treatmentCompleted todayDr. Navarro reviewed the plan by message today

Goal progress:

Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)

Follow-up: End-of-treatment visit after the last dose. Monthly liver tests and symptom review in between. Call the same day for hepatitis symptoms or a returning cough. Next scheduled visit 2026-08-18: end-of-treatment review after six months. [S]